| Income statement (USD) | Q2 2026 ended Sep 30, 2025 | Q2 2025 ended Sep 30, 2024 | Q2 2025 ended Sep 30, 2023 |
|---|---|---|---|
| Research and development | 357.4K | 265.6K | |
| Interest expense | 2.8K | 3.7K | |
| Net income | -753.3K | 141.5K | -309.7K |
From Psyence Biomedical Ltd.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.